+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment

Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment

Psychopharmacology 99(3): 322-327

Twenty-four acutely ill schizophrenic patients (DSM-III-R), 18-42 years old, were treated for 6 weeks with sulpiride. Sulpiride was administered in three different daily dosages (starting with 400, 800 or 1200 mg) according to a double blind randomized administration schedule. The monoamine metabolites (MAM) homovanillic acid (HVA), 5-hydroxy-indoleacetic acid (5-HIAA), 4-hydroxy-3-methoxy-phenylglycol (HMPG) and the amino acids tyrosine, tryptophan, glutamate and glutamine were measured in serum before treatment and once a week during treatment. There were no significant differences between healthy controls and schizophrenic patients in serum levels of monoamine metabolites and amino acids before treatment. There was no dose-response effect of sulpiride on serum levels of the monoamine metabolites or the amino acids. The results are therefore based on the whole group of patients. During treatment the HMPG levels were reduced at all points in time. The serum level of HVA was significantly reduced after 6 weeks. The 5-HIAA and the amino acid levels were not changed during treatment. There were no significant correlations among the monoamine metabolites before treatment. During treatment, however, significant correlations were found among MAM and amino acids. Since the biochemical findings during the treatment were not related to the dose or the concentration of sulpiride the results may be related to secondary biochemical effects of sulpiride and/or to changes in the clinical state following treatment.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 007566005

Download citation: RISBibTeXText

PMID: 2480613

DOI: 10.1007/bf00445551

Related references

Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology 101(3): 324-331, 1990

Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. British Journal of Psychiatry 147: 276-282, 1985

Plasma amino acids in schizophrenic patients with methionine or cysteine loading and a monoamine oxidase inhibitor. American Journal of Clinical Nutrition 24(9): 1053-1059, 1971

P-4-47 Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patients. European Neuropsychopharmacology 5(3): 341-342, 1995

Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatrica Scandinavica. Supplementum 311: 75-92, 1984

CSF monoamine metabolites in schizophrenic patients. Acta Psychiatrica Scandinavica 66(5): 350-360, 1982

Effect of parenteral amino acids on cerebral function and serum amino acids of patients with liver cirrhosis. Amino acid treatment in hepatic encephalopathy. Infusionstherapie und Klinische Ernahrung Forschung und Praxis 7(2): 88-94, 1980

Plasma-amino acids, serum lipids, and proteins after prefrontal lobotomy in seven schizophrenic patients. Yale Journal of Biology and Medicine 20(2): 175-183, 1947

Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. Pharmacopsychiatry 34(1): 27-32, 2001

CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychological Medicine 15(2): 335-340, 1985

The influence of aminazin therapy on the dynamics of certain free amino acids in the blood serum of schizophrenic patients. Zdravookhranenie Belorussii 8: 30-35, 1962

Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication. Zhonghua Shen Jing Jing Shen Ke Za Zhi 17(5): 273-277, 1984

Aggression and personality: association with amino acids and monoamine metabolites. Psychological Medicine 26(2): 323-331, 1996

Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Research 9(4): 301-308, 1983

CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites. Psychiatry Research 19(2): 93, 1986